An Extension Trial to NN1250-3585 Investigating Safety and Efficacy of NN1250 Compared to Insulin Detemir in Subjects With Type 1 Diabetes Mellitus in a Basal/Bolus Treatment Regimen (BEGIN: BB T1) [EXTENSION OF 700054073]
Latest Information Update: 28 Oct 2024
Price :
$35 *
At a glance
- Drugs Insulin degludec (Primary) ; Insulin aspart; Insulin detemir
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms BEGIN
- Sponsors Novo Nordisk
- 12 Dec 2013 New source identified and integrated (Clinical Trial Registry of India)
- 07 Mar 2013 New source identified and integrated (United Kingdom Clinical Research Network; 8340).
- 04 Feb 2013 New trial record